← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Mebias Discovery, Inc.
Philadelphia, PA
$14,321,663
Total funding
3
Grants
Funding over time
peak $4.7M · FY2018–25$5M$3.8M$2.5M$1.3M$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$14,321,663 · 3
By mechanism
UH3$7,453,877 · 1
UG3$6,867,786 · 2
Investigators at Mebias Discovery, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Not enough data
Largest grants
MEB-1170: A New Chemical Entity for the Treatment of Opioid Use Disorder$4,710,576
UG3 · FY2025 · DA
Biased Mu-Opioid Receptor Analgesics to Prevent Overdose and Opioid Use Disorders$3,146,950
UH3 · FY2020 · DA
Biased Mu-Opioid Receptor Analgesics to Prevent Overdose and Opioid Use Disorders$1,996,702
UH3 · FY2021 · DA
Biased Mu-Opioid Receptor Analgesics to Prevent Overdose and Opioid Use Disorders$1,995,232
UH3 · FY2022 · DA
Biased Mu-Opioid Receptor Analgesics to Prevent Overdose and Opioid Use Disorders$1,263,814
UG3 · FY2019 · DA
Biased Mu-Opioid Receptor Analgesics to Prevent Overdose and Opioid Use Disorders$893,396
UG3 · FY2018 · DA
Biased Mu-Opioid Receptor Analgesics to Prevent Overdose and Opioid Use Disorders$109,999
UH3 · FY2022 · DA
Biased Mu-Opioid Receptor Analgesics to Prevent Overdose and Opioid Use Disorders$109,995
UH3 · FY2023 · DA
Biased Mu-Opioid Receptor Analgesics to Prevent Overdose and Opioid Use Disorders$94,999
UH3 · FY2022 · DA